Fisher, Luminex to Develop Molecular Dx Products
 
Fisher HealthCare, a division of Thermo Fisher Scientific, and Luminex will use Luminex’s xMAP instruments and assays to jointly identify molecular diagnostic applications, Luminex said last week.  
 
Luminex, which develop and manufacture resulting products, said that by granting Fisher the US rights to its xMAP technology it gains a sales avenue through Fisher’s sales teams, its “access to key clinical accounts,” and its “extensive logistics network.”

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Penn State Hershey Medical Center staffer has admitted to lying about skipping mandatory steps of genetic cancer tests he performed, the Associated Press reports.

The genome of a rare, red bat suggests that its effective population size has been in decline for thousands of years, according to a PLOS One study.

In Nature this week: investigation into the genetics of medulloblastoma, and more.

A project in the UK is to use genomic selection to speed spruce tree growth, according to Innovators Magazine.